Haoyuan Medicine: Wholly-owned subsidiary passes FDA audit in the United States.

Haoyuan Pharmaceutical announced that its wholly-owned subsidiary, Yaoyuan Biotechnology Co., Ltd., underwent a pre-approval inspection by the U.S. FDA from June 22 to June 26, 2026, and recently received the on-site inspection report, confirming that it passed the inspection with zero defects. This marks the first time the formulation production base has passed the U.S. FDA inspection, which will help the company expand its U.S. market presence and have a positive impact on its operating performance and international competitiveness.